ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status

Table 4 Cox’s proportional hazard model analysis of prognostic factors in 489 patients with gastric cancers

Variables	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (yr)
≥ 60/ ≤ 59	1.22	0.94-1.59	0.123
Sex
Male/female	0.72	0.56-0.94	0.015	0.72	0.55-0.95	0.020
Serum CEA (ng/mL)
≥ 5.0/< 5.0	1.75	1.33-2.33	< 0.001	1.54	1.15-2.06	0.004
Tumor size (mm)
≥ 50/< 50	3.70	2.50-5.26	< 0.001	1.88	1.25-2.83	0.002
Histology
Undifferentiated/differentiated type	1.54	1.12-2.01	0.002	1.64	1.24-2.16	0.001
Lymphatic invasion
Present/absent	3.23	2.22-4.55	< 0.001	1.48	0.98-2.22	0.062
Venous invasion
Present/absent	1.89	1.45-2.44	< 0.001	1.21	0.92-1.60	0.171
Stage
Stage III, IV/I, II	9.09	5.56-14.29	< 0.001	3.77	2.30-6.17	0.023
Residual disease
Positive/negative	6.25	5.00-8.33	< 0.001	3.79	2.85-5.03	< 0.001
MMR status
Deficient/intact	0.74	0.44-1.25	0.264
ARID1A status
Abnormal/retained	1.30	0.98-1.75	0.070	1.36	1.01-1.84	0.040

HR: Hazards ratio; CEA: Carcinoembryonic antigen; MMR: Mismatch repair.